30 November 2022 - Albireo Pharma today announced that the Committee Economic Health Products has approved reimbursed access to Bylvay (odevixibat) in France following a favourable clinical assessment from the Haute Autorité de Santé for the treatment of progressive familial intrahepatic cholestasis types 1 and 2 (except for the BSEP3 subtype).

Bylvay received from the Transparency Committee an important SMR for its medical benefit and a moderate ASMR III for its improvement in medical benefit.

Read Albireo Pharma press release